Literature DB >> 18796372

Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007.

Juan de la Haba-Rodríguez1, Emilio Alba, Agustí Barnadas, Eloisa Bayo, Antonio Llombart, Ana Lluch, Miguel Martín, José Andrés Moreno-Nogueira, Gumersindo Pérez Manga, Alvaro Rodríguez-Lescure, Enrique Aranda.   

Abstract

Many important studies have changed the perspective from which breast cancer is approached, and they may change what have to date been the standards applicable to the diagnosis and treatment of breast cancer. In 2007, just over 200 oncologists from all over Spain met in Cordoba in order to review the latest evidence related to breast cancer and reach a consensus on the most important aspects of its diagnosis and treatment in different clinical situations: neoadjuvance, adjuvance and advanced disease. In view of these important changes, opinions on some specific aspects may be varied and all are justified. This document represents a review of the current state of the evidence.

Entities:  

Mesh:

Year:  2008        PMID: 18796372     DOI: 10.1007/s12094-008-0250-y

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  75 in total

Review 1.  Molecular biology of breast cancer.

Authors:  Miguel Martín
Journal:  Clin Transl Oncol       Date:  2006-01       Impact factor: 3.405

2.  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.

Authors:  Davide Mauri; Nicholas Pavlidis; John P A Ioannidis
Journal:  J Natl Cancer Inst       Date:  2005-02-02       Impact factor: 13.506

3.  Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.

Authors:  W Jonat; M Kaufmann; W Sauerbrei; R Blamey; J Cuzick; M Namer; I Fogelman; J C de Haes; A de Matteis; A Stewart; W Eiermann; I Szakolczai; M Palmer; M Schumacher; M Geberth; B Lisboa
Journal:  J Clin Oncol       Date:  2002-12-15       Impact factor: 44.544

4.  Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.

Authors:  Joseph Ragaz; Ivo A Olivotto; John J Spinelli; Norman Phillips; Stewart M Jackson; Kenneth S Wilson; Margaret A Knowling; Christopher M L Coppin; Lorna Weir; Karen Gelmon; Nhu Le; Ralph Durand; Andrew J Coldman; Mohamed Manji
Journal:  J Natl Cancer Inst       Date:  2005-01-19       Impact factor: 13.506

5.  Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.

Authors:  Andreas Polychronis; H Dudley Sinnett; Dimitri Hadjiminas; Hemant Singhal; Janine L Mansi; Dharsha Shivapatham; Sami Shousha; Jie Jiang; David Peston; Nigel Barrett; David Vigushin; Ken Morrison; Emma Beresford; Simak Ali; Martin J Slade; R Charles Coombes
Journal:  Lancet Oncol       Date:  2005-06       Impact factor: 41.316

6.  Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.

Authors:  M Overgaard; M B Jensen; J Overgaard; P S Hansen; C Rose; M Andersson; C Kamby; M Kjaer; C C Gadeberg; B B Rasmussen; M Blichert-Toft; H T Mouridsen
Journal:  Lancet       Date:  1999-05-15       Impact factor: 79.321

7.  Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Authors:  Donald A Berry; Constance Cirrincione; I Craig Henderson; Marc L Citron; Daniel R Budman; Lori J Goldstein; Silvana Martino; Edith A Perez; Hyman B Muss; Larry Norton; Clifford Hudis; Eric P Winer
Journal:  JAMA       Date:  2006-04-12       Impact factor: 56.272

8.  Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.

Authors:  M Overgaard; P S Hansen; J Overgaard; C Rose; M Andersson; F Bach; M Kjaer; C C Gadeberg; H T Mouridsen; M B Jensen; K Zedeler
Journal:  N Engl J Med       Date:  1997-10-02       Impact factor: 91.245

9.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

10.  Sequential doxorubicin and docetaxel as first-line treatment in metastatic breast cancer: a GEICAM-9801 phase II study.

Authors:  E Alba; N Ribelles; A Antón; R Pérez-Carrión; J M López-Vega; M Llanos; A Pelegri; J Florián; M Menéndez; M J Godes
Journal:  Breast Cancer Res Treat       Date:  2003-01       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.